Viamet Pharmaceuticals Reports Positive Interim Results Of Phase 2 Interdigital Tinea Pedis Study Of VT-1161
3/12/2014 8:16:59 AM
More...
|
Viamet Pharmaceuticals Reports Positive Interim Results Of Phase 2 Study Of VT-1161
2/19/2014 7:20:49 AM
More...
|
Viamet Pharmaceuticals To Present At The 32nd Annual J.P. Morgan Healthcare Conference
1/8/2014 10:38:05 AM
More...
|
Viamet Pharmaceuticals Expands Phase 2 Clinical Program With Novel Antifungal Agent VT-1161
9/24/2013 9:48:20 AM
More...
|
Viamet Pharmaceuticals Initiates Phase 2 Clinical Program With Novel Antifungal Agent VT-1161
9/6/2013 10:07:09 AM
More...
|
Viamet Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
1/3/2013 8:22:49 AM
More...
|
Viamet Pharmaceuticals Announces Agreement with National Institute of Allergy And Infectious Diseases (NIAID) to Advance Novel Class of Broad-Spectrum Antifungal Compounds
6/19/2012 10:06:56 AM
More...
|
Viamet Pharmaceuticals Appoints Richard Katz, M.D. as Chief Business and Financial Officer
3/7/2012 7:13:25 AM
More...
|
Viamet Pharmaceuticals Initiates Phase 1/2 Clinical Trial of Novel Prostate Cancer Therapy, VT-464
1/4/2012 8:29:20 AM
More...
|
Viamet Pharmaceuticals Appoints Former Novartis Corporation (NVS) Executive Marc Rudoltz, M.D. as Chief Medical Officer
11/3/2011 9:17:37 AM
More...
|
|